Tempramed expands U.S. clinician backing

Executive Summary

• Tempramed Technologies reports that over 275 physicians across the United States are recommending its VIVI Cap product to patients via the FrontrowMD platform.
• The partnership with FrontrowMD, a physician engagement and education platform, validates strong clinical demand for Tempramed’s temperature-sensitive medication protection solutions.
• This initiative reinforces Tempramed’s commercialization strategy by leveraging physician trust and clinical endorsement to drive B2C patient adoption and compliance.

Key Details

• Adoption Metrics: More than 275 physicians across the U.S. have included the VIVI Cap in offers available to their patients on the FrontrowMD platform.
• Platform Details: FrontrowMD is described as a leading physician engagement and education platform that enables physician-led product education and patient recommendations.
• Strategic Impact: The physician-driven adoption model is intended to strengthen trust, compliance, and patient engagement, serving as a scalable channel for sustained B2C demand generation.
• Product Positioning: Tempramed is positioning the VIVI Cap as a standard-of-care adjunct for temperature-sensitive medications, addressing risks associated with temperature exposure outside of pharmacy and clinic settings.
• Launch Timeline: The FrontrowMD partnership was initially launched in December 2025.
• Product Technology: The VIVI Cap utilizes aerospace-derived technology to provide continuous protection without requiring advance planning or external power, protecting medications like insulin from temperature fluctuations (e.g., moving between air-conditioned buildings and direct sunlight).
• Broader Context: This partnership complements Tempramed’s broader commercialization efforts across pharmacy, direct-to-consumer, and enterprise channels.

Notable Quotes

• Ron Nagar, CEO of Tempramed: "Physician recommendations are the most powerful drivers of patient behaviour in health care... This partnership with FrontrowMD validates that clinicians recognize temperature exposure as a real and under-addressed risk to medication effectiveness. For Tempramed, this is not just awareness it is clinical endorsement translating directly into patient adoption at scale."
• Dr. Knotresha Stewart, River Valley Healthcare Associates: "What stands out to me about the VIVI Cap is that it can provide continuous protection without requiring advance planning... When this occurs, even for short periods, it can damage the integrity of the medication."